Biocorrx Company Profile (OTCMKTS:BICX)

About Biocorrx (OTCMKTS:BICX)

Biocorrx logoBioCorRx, Inc., formerly Fresh Start Private Management, Inc., is a holding company. The Company is an addiction healthcare solutions company operating in Santa Ana, California. The Company, through its subsidiary, Fresh Start Private, Inc., provides alcoholism and opioid treatment program. It offers a medication-assisted treatment program that combines non-addictive medication coupled with psycho-social counseling. It also distributes and licenses the BioCorRx Recovery Program for alcoholism and opioid addiction treatment. The BioCorRxO Recovery Program consists of over two parts, which include an implant, administered by a licensed physician, of a compounded formulation of the drug, Naltrexone (implanted under the skin) (the Implant), which reduces alcohol cravings over a period of time, and a structured, intensive one on one counseling program developed by it. It offers BioCorRx Recovery Program in over 10 locations, including California, Arizona, Atlanta, Illinois and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:BICX
  • CUSIP: N/A
  • Web:
  • Market Cap: $19.78 million
  • Outstanding Shares: 242,136,000
Average Prices:
  • 50 Day Moving Avg: $0.09
  • 200 Day Moving Avg: $0.13
  • 52 Week Range: $0.01 - $0.34
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $628,217.00
  • Price / Sales: 31.49
  • Book Value: ($0.01) per share
  • Price / Book: -11.67
  • EBIDTA: ($2,590,000.00)
  • Net Margins: -4,981.56%
  • Return on Assets: -288.36%
  • Debt-to-Equity Ratio: -0.74%
  • Current Ratio: 0.82%
  • Quick Ratio: 0.82%
  • Average Volume: 464,841 shs.
  • Beta: 0.29

Frequently Asked Questions for Biocorrx (OTCMKTS:BICX)

What is Biocorrx's stock symbol?

Biocorrx trades on the OTCMKTS under the ticker symbol "BICX."

How were Biocorrx's earnings last quarter?

Biocorrx Inc. (OTCMKTS:BICX) issued its quarterly earnings results on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $0.17 million for the quarter. View Biocorrx's Earnings History.

When will Biocorrx make its next earnings announcement?

Biocorrx is scheduled to release their next quarterly earnings announcement on Thursday, November, 16th 2017. View Earnings Estimates for Biocorrx.

Who are some of Biocorrx's key competitors?

Who are Biocorrx's key executives?

Biocorrx's management team includes the folowing people:

  • Brady J. Granier, President, Chief Executive Officer, Director
  • Lourdes Felix, Chief Financial Officer, Chief Operating Officer, Treasurer, Director
  • Tom Welch, Director - Operations
  • Kent Emry, Director

How do I buy Biocorrx stock?

Shares of Biocorrx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocorrx's stock price today?

One share of Biocorrx stock can currently be purchased for approximately $0.08.

MarketBeat Community Rating for Biocorrx (OTCMKTS BICX)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  14 (Vote Underperform)
Total Votes:  26
MarketBeat's community ratings are surveys of what our community members think about Biocorrx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biocorrx (OTCMKTS:BICX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Biocorrx (OTCMKTS:BICX)
No equities research coverage for this company has been tracked by


Earnings History for Biocorrx (OTCMKTS:BICX)
Earnings by Quarter for Biocorrx (OTCMKTS:BICX)
Earnings History by Quarter for Biocorrx (OTCMKTS BICX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2016Q3 2016($0.02)$0.17 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biocorrx (OTCMKTS:BICX)

No earnings estimates for this company have been tracked by


Dividend History for Biocorrx (OTCMKTS:BICX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Biocorrx (OTCMKTS:BICX)
Insider Ownership Percentage: 14.85%
Insider Trades by Quarter for Biocorrx (OTCMKTS:BICX)
Insider Trades by Quarter for Biocorrx (OTCMKTS:BICX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/27/2015Jorge Andrade JrDirectorSell125,000$0.06$7,500.00View SEC Filing  
2/26/2015Jorge Andrade JrDirectorSell245,000$0.05$12,250.00View SEC Filing  
2/23/2015Jorge Andrade JrDirectorSell215,000$0.06$12,900.00View SEC Filing  
2/17/2015Jorge Andrade JrDirectorSell90,000$0.08$7,200.00View SEC Filing  
2/10/2015Jorge Andrade JrDirectorSell60,000$0.09$5,400.00View SEC Filing  
10/28/2014Jorge Andrade JrDirectorSell25,000$0.09$2,250.00View SEC Filing  
10/13/2014Jorge Andrade JrDirectorSell80,000$0.09$7,200.00View SEC Filing  
10/7/2014Jorge Andrade JrDirectorSell40,000$0.11$4,400.00View SEC Filing  
10/1/2014Jorge Andrade JrDirectorSell30,000$0.13$3,900.00View SEC Filing  
9/29/2014Jorge Andrade JrDirectorSell170,000$0.10$17,000.00View SEC Filing  
9/22/2014Jorge Andrade JrDirectorSell130,000$0.10$13,000.00View SEC Filing  
9/15/2014Jorge Andrade JrDirectorSell90,000$0.10$9,000.00View SEC Filing  
9/8/2014Jorge Andrade JrDirectorSell95,000$0.11$10,450.00View SEC Filing  
8/22/2014Jorge Andrade JrDirectorSell100,000$0.13$13,000.00View SEC Filing  
8/14/2014Jorge Andrade JrDirectorSell300,000$0.14$42,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Biocorrx (OTCMKTS:BICX)
Latest Headlines for Biocorrx (OTCMKTS:BICX)
DateHeadline logoBioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use Disorder - September 12 at 4:49 PM logoBioCorRx to Exhibit at CASAM Conference in San Francisco, California - August 21 at 4:31 PM logoBioCorRx Reports 12% Increase in Revenue and Provides Business Update for the Second Quarter of 2017 - August 15 at 5:24 PM logoBioCorRx Schedules Second Quarter 2017 Business Update & Earnings Conference Call - August 11 at 5:01 PM logoSerrano Kidney and Vascular Access Center to Implement the BioCorRx Recovery Program for the Hispanic Market in Los Angeles - July 31 at 4:31 PM logoBioCorRx Announces EnLite(TM) Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio - July 25 at 4:24 PM logoBioCorRx Announces First Addiction Treatment Center in South Florida to Implement the BioCorRx Program - July 21 at 6:11 PM logoBioCorRx to Exhibit at ASAM Conference in Dallas, Texas - July 6 at 4:07 PM logoBioCorRx CEO Brady Granier Appears on Fox 11 Morning News Los Angeles; Anaheim Residents Encouraged to Seek Treatment - June 8 at 4:41 PM logoBioCorRx Inc.: BioCorRx to Present at the 2017 Marcum Microcap Conference - June 7 at 4:13 PM logoBioCorRx to Present at the 2017 Marcum Microcap Conference - June 7 at 9:49 AM logoBioCorRx Partners with the Virtual Reality Medical Center and Physicians at Scripps Memorial Hospital for Naltrexone Implant Study, Grant Assistance and Strategic Partnerships​ - June 1 at 4:21 PM logoBioCorRx to Host Grand Opening Ribbon Cutting, Support Drug Free Anaheim Initiative in the City of Anaheim - May 30 at 12:23 PM logoBioCorRx Granted Pre-IND Meeting with FDA for BICX101 - May 25 at 5:01 PM logoBioCorRx Submits Listing Application for the NASDAQ Capital Market - May 16 at 12:38 PM logoBioCorRx Provides Business Update for the First Quarter of 2017 - May 15 at 9:04 AM logoBioCorRx CEO Brady Granier Appears on Fox & Friends - May 3 at 6:38 PM logoBioCorRx Collaborating with DynamiCare Health to Develop Mobile Application for Patients with Opioid and Alcohol Addiction - April 24 at 10:09 AM logoBioCorRx Submits Meeting Request for Pre-IND Meeting with FDA for BICX101 - April 10 at 11:43 AM logoBioCorRx Announces BICX101 Preclinical Update; ASAM Attendance - April 7 at 8:30 AM logoPrivate Equity Firm Alpine Creek Completes Equity Financing of Biotech BioCorRx - April 2 at 3:47 PM logoBioCorRx CEO Brady Granier Appears on Fox Business Network - March 28 at 1:08 PM logoBrady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc. Provide Updates and Outlook in a New Audio Interview with - March 27 at 11:10 AM logoBioCorRx Announces Upgrade to the OTCQB(R) - March 22 at 3:35 PM logoBioCorRx Announces Updates on Preclinical Studies of BICX101 and Pre-IND Meeting Request with FDA - March 21 at 4:15 PM logoBioCorRx to Present at the Sidoti & Company Spring 2017 Convention in NYC - March 15 at 4:13 PM logoBioCorRx Completes $940,000 Equity Financing and Announces Alpine Creek Capital has Agreed to Invest an Additional $1.7 Million - March 10 at 4:45 PM logoAmerica's War on Drugs - March 7 at 12:35 PM logoWho Is Winning the Fight Against Opioid Abuse? - February 27 at 3:20 PM logoBioCorRx Provides Preclinical Study Update on BICX101 Development - February 23 at 3:21 PM logoDrug Addiction Treatment Stocks to Watch - February 22 at 3:56 PM logoBioCorRx Announces the Appointment of Dr. Balbir S. Brar as VP of Drug Development - February 21 at 10:41 AM logoANGEL Program Gets National Attention - February 13 at 4:25 PM logoBioCorRx Provides Business Update Webcast - February 10 at 3:23 PM logoBIOCORRX INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - February 8 at 4:04 PM logoBioCorRx to Collaborate with the City of Anaheim to Treat Opioid and Alcohol Addiction - February 8 at 4:04 PM logo21st Century Cures Act Hopes To Reduce $41 Billion Annual Cost Of Opioid Treatments - January 22 at 3:53 PM logoJGR Capital Partners Initiates Coverage on BioCorRx Inc. with a Price Target of $0.09 - January 19 at 8:24 PM logoBioCorRx Retains Innovative Science Solutions to Guide FDA Regulatory Process for its Naltrexone Products - January 12 at 4:09 PM logoBioCorRx Inc. to Present at the 9th Annual LD Micro Main Event - December 2 at 10:13 AM logoBioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA - November 29 at 2:57 PM logoBioCorRx Inc. to Host Corporate Update Webinar on Wednesday, October 12th at 2:00 p.m. Eastern Time - October 6 at 9:21 AM logoBioCorRx Inc. Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product - September 15 at 12:44 PM logoBioCorRx Inc. Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology - August 31 at 3:49 PM logoBioCorRx, Inc. Announces Agreement With Dr. David Gastfriend to Provide Strategic Initiative and Corporate Development Consulting - August 17 at 12:00 PM logoBIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement - August 3 at 12:30 PM logoBioCorRx Retains MZ Group as Investor Relations Advisor - July 20 at 10:28 AM logoBioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant - July 14 at 8:00 AM logoAlpine Creek and BioCorRx Announce Major Investment Into BioCorRx - June 20 at 2:01 PM logoBIOCORRX INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statemen - May 20 at 5:05 PM



Biocorrx (BICX) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff